INTEGRATED BIOPHARMA, INC. (INBP) Free cash flow 2017–2026
INTEGRATED BIOPHARMA, INC. (INBP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$895,000FY2026 · since FY2017: $70,000 → $895,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $895,000 | -52.2% |
| FY2025 | $1.9M | +380.5% |
| FY2024 | $390,000 | -65.1% |
| FY2023 | $1.1M | -69.0% |
| FY2022 | $3.6M | +30.9% |
| FY2021 | $2.8M | +144.9% |
| FY2020 | $1.1M | +1408.1% |
| FY2019 | -$86,000 | -109.3% |
| FY2018 | $921,000 | +1215.7% |
| FY2017 | $70,000 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross profitINBP Gross marginINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →